Company news

Roivant Sciences Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Roivant Provides Update on Graves’ Disease Development Program

September 8, 2024

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

August 7, 2024

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

July 24, 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 29, 2024

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

May 15, 2024

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 1, 2024

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

March 25, 2024

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

February 12, 2024

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

January 29, 2024

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

December 19, 2023

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 27, 2023

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

November 26, 2023

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

November 12, 2023

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

November 9, 2023

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

October 29, 2023

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 22, 2023

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 25, 2023

Roivant Announces Completion of Redemption of its Outstanding Warrants

September 10, 2023

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

August 16, 2023

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

August 13, 2023

Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023

August 2, 2023

Roivant Announces Redemption of Outstanding Warrants

August 1, 2023

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

July 26, 2023

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

July 10, 2023

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update

June 27, 2023

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

June 25, 2023

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

June 21, 2023

Roivant to Host Investor Call at 8: 00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

June 20, 2023

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

May 15, 2023

Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research

April 3, 2023

Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

March 27, 2023

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

March 14, 2023

Roivant to Host Investor Call at 8: 00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

March 13, 2023

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

March 13, 2023

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

March 6, 2023

Roivant Sciences Announces Change to its Board of Directors

February 20, 2023

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

February 12, 2023

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

February 1, 2023

Roivant Sciences Announces Proposed Public Offering of Common Shares

January 31, 2023

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

January 29, 2023

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker...

January 3, 2023

Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases

November 30, 2022

Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update

November 13, 2022

Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC

November 9, 2022

Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering

November 7, 2022

Roivant Sciences Announces Proposed Public Equity Offering

November 6, 2022

Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences

October 17, 2022

Roivant to Participate in September Investor Events

August 29, 2022

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

August 14, 2022

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

August 2, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.